Howie Rosen is an independent consultant and serves on the board of directors of: AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), where he served as CEO from 2015-17; Entrega, Inc.; Firecycte Therapeutics, Inc.; Hammerton, Inc.; Hopewell Therapeutics, Inc.; and Kala Pharmaceuticals, Inc. (NASDAQ: KALA), where he served as Chairman from 2014-15. From 2004 to 2008, he was Vice President, Commercial Strategy at Gilead Sciences, Inc. where his responsibilities included strategic marketing, global brand management, health economics, competitive intelligence, market research and Gilead’s overall portfolio and business planning. Prior to joining Gilead, Mr. Rosen was President of ALZA Corporation where he was responsible for all aspects of managing ALZA as an independent 1000-person operating company within the Johnson & Johnson Family of Companies. Previously at ALZA as Vice President, Product Development, he was responsible for product development activities, portfolio management and corporate and new product planning. Over his 10 years at ALZA, Mr. Rosen also had responsibilities for mergers and acquisitions, R&D planning, and technology ventures. Prior to joining ALZA, Mr. Rosen managed the west coast practice of Integral, Inc., was Director, Corporate Development at GenPharm International, Inc. and was a consultant in the San Francisco office of McKinsey & Co.
Mr. Rosen is a past member of the Stanford University Advisory Council on Interdisciplinary Biosciences and the Stanford School of Engineering Advisory Council. Mr. Rosen is a member of the Biomedical Engineering Advisory Board at City College of New York and the Industrial Advisory Board for the University of North Carolina/North Carolina State Joint Biomedical Engineering Department. Previously he was a member of the BODs of Alcobra, Ltd., ALDEA Pharmaceuticals, Inc., CNS Therapeutics, Inc., CoTherix, Inc., Metera Pharmaceuticals, Inc., NTF Therapeutics, Inc., PaxVax, Inc., Pearl Therapeutics, Inc., where he served as interim President and CEO, and Pharsight Corporation.
Mr. Rosen is an Adjunct Professor in the Department of Chemical Engineering at Stanford and a Lecturer in Management at the Stanford Graduate School of Business. He is also a member of the National Academy of Engineering (NAE), a Councillor and Past-chair of the Bioengineering Section, and a Fellow of the American Institute for Medical and Biological Engineering (AIMBE). He is co-inventor on 7 US patents.
Mr. Rosen received an MBA from the Stanford Graduate School of Business, where he graduated first in his class as the Henry Ford II Scholar. Mr. Rosen has an MS in Chemical Engineering from MIT and he graduated with distinction from Stanford University with a BS in Chemical Engineering.